Table 2

Clinical trials targeting TIGIT, CD112R, and CD226

TargetDrug (manufacturer)Drug typeProtocol and tumor typesTherapeutic combinations
TIGITBMS-986207 (Bristol Myers Squibb)TIGIT blocking human IgG1 mAbPhase I/II in patients with multiple myeloma with relapseBMS-986207
or Elotuzumab (anti-SLAMF7) or Relatimab (anti-LAG-3)
+Potomalidimide
+Dexamethasone
BGB-A1217 (BeiGene)TIGIT blocking humanized IgG1 mAbPhase I/Ib in patients with metastatic solid tumorsBGB-A1217
+Tislelizumab (anti-PD-1)
Tiragolumab, MTIG7192A (Genentech)TIGIT blocking human IgG1 mAbPhase II in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancerTiragolumab or placebo
+Atezolizumab (anti-PD-L1)
Tiragolumab, MTIG7192A (Genentech)TIGIT blocking human IgG1 mAbPhase III in patients with untreated extensive-stage small lung cell cancerTiragolumab or placebo
+Atezolizumab (anti-PD-L1)
+Etoposide
+Carboplatin
Tiragolumab, MTIG7192A (Genentech)TIGIT blocking human IgG1 mAbPhase III in patients with untreated locally advanced, unresectable, or metastatic PD-L1-selected non-small cell lung cancerTiragolumab or placebo
+Atezolizumab (anti-PD-L1)
Tiragolumab, MTIG7192A (Genentech)TIGIT blocking human IgG1 mAbPhase Ib/II in patients with locally advanced unresectable or metastatic gastro-esophageal junction cancer or esophageal cancerTiragolumab
+Atezolizumab (anti-PD-L1) or Tiragolumab
+Atezolizumab (anti-PD-L1)
+Cisplatin
+5-Fluorouracil or combinations without Tiragolumab
AB154
(Arcus Biosciences)
TIGIT blocking humanized IgG1 mAbPhase I in patients with advanced solid malignanciesAB154
+Zimberelimab (anti-PD-1) or Zimberelimab alone
AB154
(Arcus Biosciences)
TIGIT blocking humanized IgG1 mAbPhase II in patients with PD-L1 positive, locally advanced or metastatic non-small cell lung cancerAB154
+Zimberelimab (anti-PD-1)
AB154
+Zimberelimab
+AB928 (anti-A2a/bR antagonist) or Zimberelimab alone
ASP8374
(Astella Pharma Global Development)
TIGIT blocking human IgG4 mAbPhase Ib in patients with advanced tumorsASP8374
+Pembrolizumab (anti-PD-1)
MK-7684 (Merck Sharp & Dohme)TIGIT blocking humanized IgG1 mAbPhase I/II in patients with melanomaMK-7684
+Pembrolizumab (anti-PD-1) or Pembrolizumab alone
MK-7684 (Merck Sharp & Dohme)TIGIT blocking humanized IgG1 mAbPhase I/II in patients with PD-1 refractory melanomaMK-7684 or Lenvatinib
+Pembrolizumab (anti-PD-1)
+MK-1308 (anti-CTLA-4)
CD112RCOM701 (Compugen)CD112R/PVRIG inhibitorPhase I in patients with advanced solid tumorsCOM701
+Nivolumab (anti-PD-1) or COM701 alone
CD226LY3435151 (Eli Lilly and Company)CD226 agonistPhase Ia/Ib in patients with advanced solid tumorsLY3435151
+Pembrolizumab (anti-PD-1) or LY3435151 alone
  • Antibodies targeting TIGIT and drugs targeting CD112R or CD226 found on ClinicalTrials.gov (as of April 2020) that are currently active in clinical trials for the indicated tumor types, with the therapeutic combination listed.

  • IgG, immunoglobulin; mAb, monoclonal antibody; PD-1, programmed cell death receptor 1.